HalioDx Plans CLIA Laboratory in Richmond, Virginia
02/20/2019
“We are very excited to start our activity with our brand new CLIA laboratory based in Richmond,” said CEO of HalioDx Inc. Stéphane Debono. “Our location in Virginia will allow us to closely interact with all laboratories and hospitals in the region while benefitting from a quite competitive offering from the local authorities, including the Virginia Bio cluster. We are now in full capacity to propose our high clinical value test Immunoscore®, and this has been possible thanks to the support of the Commonwealth and City of Richmond.”
Virginia Economic Development Partnership worked with the City of Richmond, the VA Bio+Tech Park and Greater Richmond Partnership to secure the project for Virginia. VEDP will support HalioDx’s job creation through the Virginia Jobs Investment Program (VJIP), which provides consultative services and funding to companies creating new jobs or experiencing technological change.
“HalioDx’s decision to establish a new facility in the City of Richmond is an exciting step forward for the company and the Commonwealth,” said Secretary of Commerce and Trade Brian Ball. “Biotechnology in the 21st century is evolving rapidly, and innovative firms like HalioDx help drive Virginia’s reputation as a leader in this vital sector. The company is sure to thrive in its new home in the VA Bio+Tech Park, and we thank HalioDx for its investment in the City of Richmond and the Commonwealth.”
“HalioDx is an international company that is making groundbreaking advances in biosciences, and choosing Virginia as its gateway into the U.S. market is a testament to our world-class amenities, strategic location, and innovative spirit,” said Governor Ralph Northam. “My administration is laser focused on strengthening Virginia’s bioscience economy, and I am confident that Richmond offers the ideal launch pad for HalioDx’s future growth in the Commonwealth.”
“I am delighted HalioDx has chosen to locate its U.S. headquarters in the heart of Richmond’s downtown VA Bio+Tech Park,” said City of Richmond Mayor Levar Stoney. “We were recently named a ‘best location for biosciences in Virginia’ as well as a ‘top mid-sized city for foreign direct investment,’ which is why Richmond is where a foreign biotechnology firm like HalioDx will excel in the United States.”
“We are thrilled to welcome HalioDx to the VA Bio+Tech Park community,” said President & CEO of VA Bio+Tech Park Carrie Roth. “The talent and knowledge HalioDx adds to our vibrant innovation ecosystem is impressive, and we’re excited to support the company as it grows its presence in the U.S.”
“The VA Bio+Tech Park has been a phenomenal asset for the City of Richmond and Virginia, and HalioDx will undoubtedly be a strong addition to the thriving network of biotechnology companies here in the 71st District,” said Delegate Jeffrey Bourne. “I am honored to welcome this global company to Richmond and look forward to HalioDx’s continued success.”
Project Announcements
Hoover Treated Wood Products Plans Fairfield, Texas, Wood Treating Facility
03/30/2023
EnerVenue Establishes Shelby County, Kentucky, Manufacturing Complex
03/30/2023
LG Energy Solution Plans Queen Creek, Arizona, EV Battery Manufacturing Plant
03/28/2023
Middle West Spirits Expands Columbus, Ohio, Operations
03/28/2023
Textile Manufacture 23 Farrar Street Relocates-Plans Lynn, Massachusetts, Operations
03/28/2023
Canada-Based Epsilon Industries Plans Tuscaloosa, Alabama, Prefabricated Modular Utility Systems Plant
03/28/2023
Most Read
-
37th Annual Corporate Survey: Economic Pressures Exerting Greatest Effect on Decision-Makers
Q1 2023
-
19th Annual Consultants Survey: Clients Challenged by Tight Labor Market, Energy Availability
Q1 2023
-
The Top Investment Location Prospects for Aerospace Manufacturing
Q1 2023
-
2022 Top States for Doing Business Provide an Environment for Business Growth
Q3 2022
-
Companies Are Recalibrating Their Priorities
Q1 2023
-
Strategies to Overcome Intensifying Industrial Real Estate Challenges
Q1 2023
-
Energy Costs Come to the Forefront
Q1 2023